Nephro-Urology Monthly

Published by: Kowsar

Immunosuppression in Renal Transplantation and Dyslipidemia, Which Factors Should Be Considered?

Alfredo De Giorgi 1 and Fabio Fabbian 1 , *
Authors Information
1 Department of Medical Science, University of Ferrara, University Hospital S. Anna, Ferrara, Italy
Article information
  • Nephro-Urology Monthly: November 01, 2013, 5 (5); 1008-1009
  • Published Online: November 13, 2013
  • Article Type: Letter
  • Received: August 13, 2013
  • Accepted: September 3, 2013
  • DOI: 10.5812/numonthly.14189

To Cite: De Giorgi A, Fabbian F. Immunosuppression in Renal Transplantation and Dyslipidemia, Which Factors Should Be Considered?, Nephro-Urol Mon. 2013 ; 5(5):1008-1009. doi: 10.5812/numonthly.14189.

Copyright © 2013, Nephrology and Urology Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
Footnotes
References
  • 1. Gaddi A, Cicero AF, Odoo FO, Poli AA, Paoletti R. Practical guidelines for familial combined hyperlipidemia diagnosis: an up-date. Vasc Health Risk Manag. 2007; 3(6): 877-86[PubMed]
  • 2. Fabbian F, Bergami M, Molino C, De Giorgi A, Pala M, Longhini C, et al. Risk factors for metabolic syndrome in stable Italian renal transplant patients. Clin Exp Nephrol. 2011; 15(4): 560-6[DOI][PubMed]
  • 3. Collins AJ, Foley RN, Herzog C, Chavers B, Gilbertson D, Ishani A, et al. US Renal Data System 2012 Annual Data Report. Am J Kidney Dis. 2013; 61(1 Suppl 1)-476[DOI][PubMed]
  • 4. Fabbian F, De Giorgi A, Pala M, Tiseo R, Manfredini R, Portaluppi F. Evidence-based statin prescription for cardiovascular protection in renal impairment. Clin Exp Nephrol. 2011; 15(4): 456-63[DOI][PubMed]
  • 5. Berg AL, Nilsson-Ehle P. ACTH lowers serum lipids in steroid-treated hyperlipemic patients with kidney disease. Kidney Int. 1996; 50(2): 538-42[PubMed]
  • 6. Kuster GM, Drexel H, Bleisch JA, Rentsch K, Pei P, Binswanger U, et al. Relation of cyclosporine blood levels to adverse effects on lipoproteins. Transplantation. 1994; 57(10): 1479-83[PubMed]
  • 7. Deters M, Kirchner G, Koal T, Resch K, Kaever V. Everolimus/cyclosporine interactions on bile flow and biliary excretion of bile salts and cholesterol in rats. Dig Dis Sci. 2004; 49(1): 30-7[PubMed]
  • 8. Hosseini MS, Rostami Z, Einollahi B. Dyslipidemia after kidney trasplantation an correlation with Cylosporine level. Nephr Urol Mon. 2013; 5(3): 831-4
  • 9. Laufer G, Grablowitz V, Laczkovics A, Miholic J, Heinz G, Wollenek G, et al. The determinants of elevated total plasma cholesterol levels in cardiac transplant recipients administered low dose cyclosporine for immunosuppression. J Thorac Cardiovasc Surg. 1992; 104(2): 241-7[PubMed]
  • 10. Hricik DE, Mayes JT, Schulak JA. Independent effects of cyclosporine and prednisone on posttransplant hypercholesterolemia. Am J Kidney Dis. 1991; 18(3): 353-8[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments